CXCR6+ T Cells Drive Immune Checkpoint Inhibitor Myocarditis
This study identified CXCR6+ T cells as key drivers of immune checkpoint inhibitor-associated myocarditis, particularly with combination ICI therapy including anti-LAG-3 agents. The mechanistic insight may guide future prevention and treatment strategies for this serious complication.
Summary
BACKGROUND:Myocarditis is a severe complication of immune checkpoint inhibitors (ICIs). The major risk factor for ICI myocarditis is the use of combination ICI treatment, especially when relatlimab, a novel anti–LAG-3 (lymphocyte-activation gene 3) antibody, is combined with anti–PD-1 (programmed cell death protein 1) therapy. Although pathogenic T cells are necessary for ICI myocarditis, the specific signaling and T-cell populations that drive cardiac infiltration have not been fully elucidated, especially in setting of anti–LAG-3/PD-1 treatment.METHODS:We used VigiBase, an international pharmacovigilance database, to assess the risk of myocarditis with anti–LAG-3 compared with other ICI treatment regimens. We identified a mouse model of LAG-3/PD-1–associated ICI myocarditis through genetic deletion of immune checkpoints LAG-3 and PD-1 (Lag3-/-, Pdcd1-/-mice) and performed rigorous cardiac phenotyping using histology, flow cytometry, electrocardiography, single-cell RNA sequencing, an
Join us
Join the Global Primary Care Cardio Network. Membership is free.
Would you like to tell us more about yourself?
Interests
We will send you an email with a link to confirm your registration.